https://doi.org/10.4081/reumatismo.2021.1445

Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis

Vol. 73 No. 3 (2021)
Submitted: 27 July 2021
Accepted: 16 September 2021
Published: 22 November 2021
COVID-19, COVID-19 vaccine, herpes zoster, rheumatology.
Abstract Views: 6959
PDF: 905
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

B. Maranini
beatrice.maranini@edu.unife.it
https://orcid.org/0000-0002-7313-3520
Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.
G. Ciancio
Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.
R. Cultrera
Infectious Diseases, Department of Translational Medicine, University of Ferrara, Italy.
M. Govoni
Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.

Since the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic outbreak, vaccines gained a growing role. Possible vaccine-related side effects range from minor local events to more prominent systemic manifestations up to anaphylactic reactions. A heterogeneous spectrum of cutaneous reactions has been reported, ranging from local injection site reactions to urticarial and morbilliform eruptions, pernio/chilblains and zoster flares. Here, we describe a case of varicella zoster virus reactivation following mRNA coronavirus 2019 vaccine and discuss the available literature upon the topic published so far.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27). [Epub ahead of print].
Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013; 369: 255-63. DOI: https://doi.org/10.1056/NEJMcp1302674
Walter R, Hartmann K, Fleisch F, et al. Reactivation of herpesvirus infections after vaccinations? Lancet (London, England). 1999; 353: 810. DOI: https://doi.org/10.1016/S0140-6736(99)00623-6
Bostan E, Yalici-Armagan B. Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? J Cosmet Dermatol. 2021; 20: 1566-7. DOI: https://doi.org/10.1111/jocd.14035
Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021; 93: 5231-2. DOI: https://doi.org/10.1002/jmv.27036
McMahon DE, Amerson A, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021; 85: 46-55. DOI: https://doi.org/10.1016/j.jaad.2021.03.092
Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford, England). 2021. [Epub ahead of print]. DOI: https://doi.org/10.1093/rheumatology/keab702
Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019; 10: 594. DOI: https://doi.org/10.3389/fimmu.2019.00594
Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5: e001041. DOI: https://doi.org/10.1136/rmdopen-2019-001041

How to Cite

Maranini, B., Ciancio, G., Cultrera, R., & Govoni, M. (2021). Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis. Reumatismo, 73(3). https://doi.org/10.4081/reumatismo.2021.1445

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.